These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 28222041)

  • 1. A comparison of short-term therapeutic efficacy between infliximab and tacrolimus for moderate to severe ulcerative colitis.
    Yamagami H; Nishida Y; Nagami Y; Hosomi S; Yukawa T; Otani K; Tanaka F; Taira K; Kamata N; Tanigawa T; Shiba M; Watanabe T; Fujiwara Y
    Rom J Intern Med; 2017 Sep; 55(3):151-157. PubMed ID: 28222041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-Term and Long-Term Outcomes of Infliximab and Tacrolimus Treatment for Moderate to Severe Ulcerative Colitis: Retrospective Observational Study.
    Otsuka T; Ooi M; Tobimatsu K; Wakahara C; Watanabe D; Adachi S; Yasutomi E; Yamairi H; Ku Y; Yoshida M; Hoshi N; Kodama Y
    Kobe J Med Sci; 2018 Dec; 64(4):E140-E148. PubMed ID: 30728340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the therapeutic efficacy and safety between tacrolimus and infliximab for moderate-to-severe ulcerative colitis: a single center experience.
    Nuki Y; Esaki M; Asano K; Maehata Y; Umeno J; Moriyama T; Nakamura S; Matsumoto T; Kitazono T
    Scand J Gastroenterol; 2016; 51(6):700-5. PubMed ID: 26818468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Safety and Efficacy of Tacrolimus versus Infliximab for Active Ulcerative Colitis.
    Takeuchi K; Shimoyama T; Yamamoto T
    Dig Dis; 2018; 36(2):106-112. PubMed ID: 29050007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pooled analysis of the comparative efficacy between tacrolimus and infliximab for ulcerative colitis.
    Liu YJ; Fan H; Zhen WW; Yu X; Chen JT; Wang CD
    Medicine (Baltimore); 2018 Aug; 97(32):e11440. PubMed ID: 30095612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of infliximab, cyclosporine and tacrolimus on ulcerative colitis: A meta-analysis.
    Jia X; Guo R; Hu Z; Liu J; Liu J; Li B; Yang Q; He J
    Medicine (Baltimore); 2020 Oct; 99(44):e22894. PubMed ID: 33126341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy and safety of infliximab and calcineurin inhibitors in steroid-refractory UC patients: A meta-analysis.
    Zhao HN; Jiang M; Sun MJ; Dai C
    Saudi J Gastroenterol; 2021; 27(4):191-200. PubMed ID: 34380865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Effectiveness of Tacrolimus and Infliximab in Hospitalized Patients With Ulcerative Colitis.
    Takahashi T; Shiga H; Tarasawa K; Shimoyama Y; Naito T; Moroi R; Kuroha M; Kakuta Y; Fushimi K; Fujimori K; Kinouchi Y; Masamune A
    Clin Transl Gastroenterol; 2024 Jan; 15(1):e00642. PubMed ID: 37753937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tacrolimus or infliximab for severe ulcerative colitis: short-term and long-term data from a retrospective observational study.
    Minami N; Yoshino T; Matsuura M; Koshikawa Y; Yamada S; Toyonaga T; Madian A; Honzawa Y; Nakase H
    BMJ Open Gastroenterol; 2015; 2(1):e000021. PubMed ID: 26462273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tacrolimus vs. anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis: a retrospective observational study.
    Yamamoto T; Shimoyama T; Umegae S; Matsumoto K
    Aliment Pharmacol Ther; 2016 Mar; 43(6):705-16. PubMed ID: 26762838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful use of infliximab and tacrolimus combination therapy in a patient with ulcerative colitis refractory to infliximab dose intensification plus azathioprine.
    Cortes X; Borrás-Blasco J; Fernendez S; Moreno M; Rodríguez J; Molés JR; Casterá E
    Int J Clin Pharmacol Ther; 2016 Feb; 54(2):125-8. PubMed ID: 26754306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effectiveness and safety of infliximab and adalimumab in patients with ulcerative colitis.
    Singh S; Heien HC; Sangaralingham LR; Schilz SR; Kappelman MD; Shah ND; Loftus EV
    Aliment Pharmacol Ther; 2016 May; 43(9):994-1003. PubMed ID: 26991059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Similar Short- and Long-term Colectomy Rates with Ciclosporin and Infliximab Treatment in Hospitalised Ulcerative Colitis Patients.
    Duijvis NW; Ten Hove AS; Ponsioen CI; van den Brink GR; Buskens CJ; Bemelman WA; Te Velde AA; D'Haens GR; Löwenberg M
    J Crohns Colitis; 2016 Jul; 10(7):821-7. PubMed ID: 26818660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical outcome after discontinuation of infliximab in patients with ulcerative colitis in deep remission].
    Muñoz Villafranca C; Bravo Rodríguez MT; Ortiz de Zárate J; Arreba González P; García Kamiruaga I; Heras Martín JI; Cabezudo Gil P; Orive Cura V
    Gastroenterol Hepatol; 2016; 39(7):442-8. PubMed ID: 26948837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Comparison of Short- and Long-Term Therapeutic Outcomes of Infliximab- versus Tacrolimus-Based Strategies for Steroid-Refractory Ulcerative Colitis.
    Endo K; Onodera M; Shiga H; Kuroha M; Kimura T; Hiramoto K; Kakuta Y; Kinouchi Y; Shimosegawa T
    Gastroenterol Res Pract; 2016; 2016():3162595. PubMed ID: 26904108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histological healing after infliximab induction therapy in children with ulcerative colitis.
    Wiernicka A; Szymanska S; Cielecka-Kuszyk J; Dadalski M; Kierkus J
    World J Gastroenterol; 2015 Oct; 21(37):10654-61. PubMed ID: 26457025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcomes of infliximab treatment and predictors of response in 195 patients with ulcerative colitis: a hospital-based cohort study from Korea.
    Seo H; Chang K; Lee SH; Song EM; Kim GU; Seo M; Lee HS; Hwang SW; Yang DH; Kim KJ; Ye BD; Byeon JS; Myung SJ; Yang SK; Park SH
    Scand J Gastroenterol; 2017 Aug; 52(8):857-863. PubMed ID: 28502189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis.
    Armuzzi A; Pugliese D; Danese S; Rizzo G; Felice C; Marzo M; Andrisani G; Fiorino G; Nardone OM; De Vitis I; Papa A; Rapaccini GL; Guidi L
    Inflamm Bowel Dis; 2014 Aug; 20(8):1368-74. PubMed ID: 24983979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-induction infliximab trough levels and disease activity in the clinical evolution of pediatric ulcerative colitis.
    Moore H; Dolce P; Devas N; Baldassano R; Martinelli M
    United European Gastroenterol J; 2020 May; 8(4):425-435. PubMed ID: 32213038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extent of Early Clinical Response to Infliximab Predicts Long-term Treatment Success in Active Ulcerative Colitis.
    Murthy SK; Greenberg GR; Croitoru K; Nguyen GC; Silverberg MS; Steinhart AH
    Inflamm Bowel Dis; 2015 Sep; 21(9):2090-6. PubMed ID: 26099066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.